Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label Pilot Study to Evaluate the Safety and Feasibility of an Additional Intralymphatic Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes

NCT05351879 is registered in ClinicalTrials.gov with Linkoeping University as lead sponsor.

NCT NCT05351879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label Pilot Study to Evaluate the Safety and Feasibility of an Additional Intralymphatic Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes
Lead sponsor
Linkoeping University
Phase
Phase 1/2
Overall status
Completed
Start date
May 9, 2022
Completion date
August 29, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1